Image credit: Graphic design by Dr. Veronique Juvin, Genedata.
Biomarkers are strategic assets for biopharma companies, significantly improving the success rate of clinical trials1. Yet, discovering them often feels like navigating through a blizzard of unstructured information, searching for the one true signal that can guide the way. While laboratory automation has eased benchwork, the real storm rages in the data, obscuring access to valuable scientific insights.
Data obstacles on the path to biomarker discovery
Omics, cytometry, imaging, and other technologies have deepened our understanding of health and disease. However, they yield massive, complex datasets, difficult to store, harmonize, and interpret. Scientists often struggle to automatically capture assay data from diverse instruments, annotate it consistently with sample related information, and process it efficiently and reliably. Tracing how data was handled, what parameters were applied, and how results were derived, to revisit and refine, is equally difficult. Without a scalable, interconnected software infrastructure, standardized analytical workflows, and transparent data lineage, the journey from raw data to assay result remains slow, fragmented, and uncertain.
Moreover, deriving scientifically meaningful, predictive parameters to inform clinical trial design requires more than just individual experimental results. It demands cross-assay analysis and multi-modal data integration (e.g., with patient demographic and clinical data) to capture the full complexity of a biological condition and understand its clinical relevance. This process hinges on complex data curation and modeling, a burden which typically falls on a small group of highly skilled bioinformaticians and data scientists. Without standardized, end-to-end workflows and integrated systems, scientists are forced to rely on disconnected tools and custom scripts. These fragmented approaches jeopardize data quality and integrity, which can lead to costly setbacks, wasting years of research, billions in investment, and delaying life-saving treatments. In addition, the use of handcrafted pipelines for biomarker discovery and predictive modeling limits scalability as well as reproducibility and may fail to comply with regulatory requirements. In a field where precision is everything, the risks are immense.
From assay to insight: Automating the biomarker discovery pipeline
Biopharma is entering a new phase of digital transformation. While automation in assay execution is underway, the next frontier lies in automating assay analysis and integration of experimental outputs to fuel AI-powered biomarker discovery. How can teams streamline the journey from experimental assay to validated biomarkers, while making the process faster, more scalable, and accessible to scientists without coding expertise? Here’s how a fully automated, end-to-end pipeline built for compliance, reproducibility, and speed can work in practice.
After a new batch of samples completes an experimental procedure, data is automatically captured and streamed from instruments into a secure, centralized platform. The system ingests both assay-specific output and rich metadata such as sample IDs, species, reagents, disease models, and timepoints in real time. This ingestion pipeline not only aggregates data but also processes, quality-checks, and annotates the data within a unified workflow, unlocking considerable benefits for scientists.
This automation allows for vast amounts of data to be imported and transformed faster, scaling with growing data sources and formats, while minimizing manual data entry mistakes, duplicates, and inconsistencies. Finally, automated data preparation with a complete audit trail ensures the large data pool is uniformly annotated, structured, and clean for improved findability and usability.
From there, the platform applies out-of-the-box assay-specific workflows to analyze data consistently, delivering reliable, reproducible results. Everything, from raw, processed to analyzed data, is organized into intuitive, project-based folders for discoverability and traceability. Scientists can then explore these scientific outputs from a centralized repository via a searchable catalog or simply ask an AI assistant to retrieve what they need. Bringing all this data in one place has a great benefit for scientists. As one industry expert puts it “Having a single point of access to all data you may need facilitates finding unexpected correlations, accelerating the time-to-insights.”
Once relevant experimental data sets are identified, the platform allows scientists to integrate them with phenotypic information, converting them into analysis-ready data products for downstream biomarker discovery. Built-in, use-case-specific, reproducible pipelines powered by machine learning or advanced statistics enable users to perform a wide range of analyses, from dimensionality reduction, feature selection, clustering, to predictive modeling, without writing a single line of code. Researchers can then validate findings against public or commercial datasets as well as automatically generate audit-ready reports, supporting cross-team collaboration, transparency, and regulatory submissions.
This is a rapidly emerging reality where automation doesn’t just speed up experiments but accelerates discovery itself.
Conclusion
The future of drug development hinges on our ability to extract meaningful insights, faster, more accurately, and at a scale— find the signals in the data storm.
As biomedical research grows in complexity, software-driven automation has become a foundational necessity. By dismantling data silos and connecting fragmented processes into a unified workflow, digital platforms become engines behind scalable, reproducible, and regulatory-ready biomarker discovery processes. They empower researchers to cleanse the data swamp and turn it into a data lake with confidence to transform chaos into clarity and noise into insight.
Authors:
Johannes Eichner, Ph.D. is a Principal Scientific Consultant at Genedata, leading data science projects in biomarker discovery, spanning quality-controlled data processing, data harmonization, integrative analysis, and advanced visualization.
Justyna Lisowska, Ph.D. is a Scientific Communication Manager at Genedata, transforming complex scientific insights into clear, compelling narratives, specializing in precision medicine and how digital platforms can accelerate translational science.
Image credit: Graphic design by Dr. Veronique Juvin, Genedata
References
- Kraus VB. Biomarkers as drug development tools: discovery, validation, qualification and use.
Nature Reviews Rheumatology. 2018;14:354–362. doi:10.1038/s41584-018-0005-9.
↩︎
Filed Under: clinical trials, Data science, machine learning and AI, Omics/sequencing
